A clinical study testing revumenib, a novel targeted treatment, found 40% of patients with acute leukemia had complete response and showed how the cancer cells resist the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
Researchers at Dana-Farber Cancer Institute developed a method to detect inflammation in the body using positron emission tomography imaging. This innovative probe targets CD45, a marker abundantly expressed on all immune cells but absent from other cell types.
